Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | polymerase (DNA directed) iota | Starlite/ChEMBL | No references |
Human immunodeficiency virus 1 | Aberrant vpr protein | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | unspecified product | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Leishmania major | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0023 | 0.5 | 0.5 |
Echinococcus granulosus | terminal deoxycytidyl transferase rev1 | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.5 | 0.5 |
Schistosoma mansoni | DNA polymerase eta | 0.0023 | 0.5 | 0.5 |
Loa Loa (eye worm) | ImpB/MucB/SamB family protein | 0.0023 | 0.5 | 0.5 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0023 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.5 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.5 | 0.5 |
Echinococcus multilocularis | dna polymerase eta | 0.0023 | 0.5 | 0.5 |
Leishmania major | DNA polymerase kappa, putative,DNA polymerase IV, putative | 0.0023 | 0.5 | 0.5 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0023 | 0.5 | 0.5 |
Leishmania major | DNA polymerase eta, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Echinococcus granulosus | dna polymerase eta | 0.0023 | 0.5 | 0.5 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.5 | 0.5 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.5 | 0.5 |
Echinococcus multilocularis | dna polymerase kappa | 0.0023 | 0.5 | 0.5 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.5 | 0.5 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Schistosoma mansoni | terminal deoxycytidyl transferase | 0.0023 | 0.5 | 0.5 |
Echinococcus granulosus | dna polymerase kappa | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma cruzi | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.5 | 0.5 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.5 | 0.5 |
Echinococcus multilocularis | terminal deoxycytidyl transferase rev1 | 0.0023 | 0.5 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.5 | 0.5 |
Schistosoma mansoni | rab geranylgeranyl transferase alpha subunit | 0.0023 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 14.1254 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the HIV-1 protein Vpr. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 15.8489 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 25.1189 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | = 50.1187 um | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Schistosoma Mansoni Peroxiredoxins. (Class of assay: confirmatory) [Related pubchem assays: 1011 (Confirmation Concentration-Response Assay for Inhibitors of the Schistosoma mansoni Redox Cascade ), 448 (Schistosoma Mansoni Peroxiredoxins (Prx2) and thioredoxin glutathione reductase (TGR) coupled assay)] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488771] | ChEMBL. | No reference |
Potency (functional) | = 79.4328 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PubChem BioAssay. qHTS for Antagonist of cAMP-regulated guanine nucleotide exchange factor 3 (EPAC1): primary screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 100 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.